Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

NT-proBNP predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Effects of Dapagliflozin, Metformin or Exercise on Markers of Cardiometabolic Risk: The PRE-D Trial

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  2. National trends in the use of lipid-lowering drugs among type 2 diabetes patients in Denmark from 1997 to 2017

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  3. Safety, adherence and treatment satisfaction to dapagliflozin, metformin or exercise in individuals with prediabetes: The PRE-D Trial

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  4. Effects of Dapagliflozin, Metformin or Exercise on Glycaemic Variability and Mean Glucose Levels in Prediabetes: The PRE-D Trial

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  5. Improvements in albuminuria and chronic kidney disease progression with the appetite suppressant lorcaserin

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Sodium retention and volume overload are main determinants of poor response to RAAS inhibition in patients with diabetes. As volume excess can exist without symptoms, biomarkers are needed to identify a priori which patients are volume overloaded and may experience less benefit from RAAS inhibition. N-terminal pro-brain natriuretic peptide (NT-proBNP) is released in the setting of increased cardiac wall stress and volume overload. We conducted a post-hoc analysis among 5081 patients with type 2 diabetes mellitus participating in the ALTITUDE trial to investigate whether NTproBNP can predict the effects of additional therapy with aliskiren on cardio-renal endpoints. Aliskiren compared to placebo reduced the risk of the primary cardio-renal endpoint events by 20% (95%CI: 16 to 61) and 2% (-42 to 30) in the two lowest NT-proBNP tertiles, and it increased the risk by 25% (-4 to 96) in the highest NT-proBNP tertile (p-value for trend = 0.009). Similar trends were observed for the cardiovascular and ESRD end points. Effects of aliskiren compared to placebo on safety outcomes (hyperkalemia and hospitalization for acute kidney injury) were independent of NT-proBNP. In conclusion, baseline NT-proBNP may be used as a marker to predict the response to aliskiren on cardio-renal outcomes when added to standard therapy with RAAS inhibition. This article is protected by copyright. All rights reserved.

OriginalsprogEngelsk
TidsskriftDiabetes, Obesity and Metabolism Online
Vol/bind20
Udgave nummer12
Sider (fra-til)2899-2904
Antal sider5
ISSN1463-1326
DOI
StatusUdgivet - dec. 2018

ID: 54755479